Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
ERAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $3.45
Previous CloseN/A
Volume148.24K
Average Volume (3M)1.56M
Market Cap
$388.07M
Enterprise Value$463.52M
Total Cash (Recent Filing)$360.49M
Total Debt (Recent Filing)$18.79M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 08, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding283,265,720
10 Day Avg. Volume2,239,890
30 Day Avg. Volume1,561,773
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)749.69
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$5.00Price Target Upside316.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Erasca News
See All ERAS News
---
Bulls Say, Bears Say
Bulls Say
Clinical DataPreclinical data for molecular glue assets ERAS-0015 and ERAS-4001 has impressed, showing significant potency and tumor regression potential.
Product DevelopmentErasca is developing both a pan-RAS and a pan-KRAS, positioning itself to be competitive in the RAS-driven tumor landscape.
Regulatory ApprovalERAS has received alignment on its approval strategy from both the US and EU regulatory agencies for a tissue-specific indication in melanoma.
ValuationErasca's stock is considered undervalued, with a target price implying a significant increase in its valuation.
Bears Say
Market CompetitionEfficacy in non-melanoma tumor types was limited, with a 23% response rate, which was anticipated given the complex MAPK feedback across different tissue types.
RisksThere are risks associated with the pre-IND asset, which could affect the company's future performance.
---
Ownership Overview
22.57% Insiders
10.56% Mutual Funds
<0.01% Other Institutional Investors
57.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.20 and its highest was $3.45 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $388.07M.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Mar 20, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.125 by $0.015.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.12.
How many shares outstanding does Erasca have?
Erasca has 283,265,720 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.125. Following the earnings report the stock price went up 3.378%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
---
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (316.67% Upside)
$5.00 (316.67% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 67.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.21%
12-Months-Change
Fundamentals
Return on Equity
-43.68%
Trailing 12-Months
Asset Growth
27.13%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
---
ERAS Stock 12 Month Forecast
Average Price Target
$5.00
▲(316.67% Upside)
Technical Analysis
Fate Therapeutics
―
Blueprint Medicines
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering ERAS
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-20.46%
reiterated a buy rating 14 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -20.46% per trade.
---